Drug repurposing in Raynaud's phenomenon through adverse event signature matching in the World Health Organization pharmacovigilance database.
Putkaradze ZazaMatthieu RoustitCracowski Jean-LucCharles KhouriPublished in: British journal of clinical pharmacology (2020)
Our ADR signature matching approach suggests that alemtuzumab and fumaric acid could be effective treatments of secondary RP. The latter is currently being investigated as a treatment of pulmonary hypertension in systemic sclerosis.